Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

67
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
67
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

41
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
41
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

30
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
30
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

1.4K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.4K
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

44
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
44

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Serotonin 5-HT7 receptor signaling modulates inflammatory responses and survival after myocardial infarction.

Journal of translational medicine·2026
Same author

RNA splicing and cardiovascular disease: a guide for cardiologists.

European heart journal·2026
Same author

The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial.

Nature medicine·2026
Same author

Time- and spatially resolved LNA delivery via thermally controlled SPION technology.

Molecular therapy. Nucleic acids·2026
Same author

mRNA-based SARS-CoV-2 vaccines: intracellular processing and aggregation of the encoded spike protein as a mechanistic contributor to cardiac cellular stress.

Frontiers in immunology·2026
Same author

Cardiogenic shock complicating peripartum cardiomyopathy benefits from combination therapy with levosimendan and bromocriptine.

European journal of heart failure·2026
Same journal

Molecular mechanisms of coronary microembolization-induced MINOCA.

Basic research in cardiology·2026
Same journal

Protection against postoperative atrial fibrillation via antiplatelet aggregation induced by remote ischemic preconditioning during off-pump coronary artery bypass grafting.

Basic research in cardiology·2026
Same journal

Peroxisomal catalase and plasmalogen biosynthesis protect from oxidative stress in Barth syndrome cardiomyopathy.

Basic research in cardiology·2026
Same journal

Bicuspid aortic valve stenosis is characterized by increased angiogenesis, inflammation, and a higher valvular-to-systemic calcification ratio than tricuspid aortic valve stenosis.

Basic research in cardiology·2026
Same journal

Myofilament-level effects of aficamten increase diastolic chamber volumes and maintain cardiac output through preserved length-dependent force generation in healthy rat and canine myocardium.

Basic research in cardiology·2026
Same journal

Functional rejuvenation of endothelial cell aging by transient reprogramming.

Basic research in cardiology·2026
See all related articles

Related Experiment Video

Updated: Sep 19, 2025

Ultrasound-Guided Induced Pluripotent Stem Cell-Derived Cardiomyocyte Implantation in Myocardial Infarcted Mice
08:03

Ultrasound-Guided Induced Pluripotent Stem Cell-Derived Cardiomyocyte Implantation in Myocardial Infarcted Mice

Published on: March 30, 2022

1.7K

Exploring hiPSC-CM replacement therapy in ischemic hearts.

Giuseppe Cipriano1, Thomas Thum1, Natalie Weber2,3

  • 1Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School, 30625, Hannover, Germany.

Basic Research in Cardiology
|June 10, 2025
PubMed
Summary
This summary is machine-generated.

Cardiovascular research is exploring new ways to regenerate the heart after damage, focusing on cell therapies like induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) to replace lost heart cells and improve function.

Keywords:
Cell therapyHuman induced pluripotent stem cell-derived cardiomyocytesIschemic heart disease

More Related Videos

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
08:47

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes

Published on: December 16, 2022

2.5K
Pluripotent Stem Cell Derived Cardiac Cells for Myocardial Repair
06:37

Pluripotent Stem Cell Derived Cardiac Cells for Myocardial Repair

Published on: February 3, 2017

8.4K

Related Experiment Videos

Last Updated: Sep 19, 2025

Ultrasound-Guided Induced Pluripotent Stem Cell-Derived Cardiomyocyte Implantation in Myocardial Infarcted Mice
08:03

Ultrasound-Guided Induced Pluripotent Stem Cell-Derived Cardiomyocyte Implantation in Myocardial Infarcted Mice

Published on: March 30, 2022

1.7K
Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
08:47

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes

Published on: December 16, 2022

2.5K
Pluripotent Stem Cell Derived Cardiac Cells for Myocardial Repair
06:37

Pluripotent Stem Cell Derived Cardiac Cells for Myocardial Repair

Published on: February 3, 2017

8.4K

Area of Science:

  • Cardiovascular Research
  • Regenerative Medicine
  • Cardiac Cell Therapy

Background:

  • Ischemic heart disease leads to heart failure and death globally.
  • Myocardial infarction causes cardiomyocyte loss, driving heart remodeling and failure.
  • Current treatments slow remodeling but don't address cardiomyocyte loss or regeneration.

Purpose of the Study:

  • To review the evolution of cardiac cell therapy for heart regeneration.
  • To highlight recent advancements in replacing lost cardiomyocytes.
  • To discuss challenges in translating cell therapy into clinical practice.

Main Methods:

  • Investigating non-coding RNA manipulation (lncRNA, circRNA, miRNA).
  • Utilizing growth factors to promote cardiomyocyte cell cycle re-entry.
  • Exploring direct reprogramming of fibroblasts into cardiomyocytes (CMs).
  • Developing induced pluripotent stem cell (iPSC) reprogramming and differentiation protocols to generate iPSC-derived cardiomyocytes (iPSC-CMs).
  • Enhancing iPSC-CM therapy through anti-apoptotic strategies and tissue engineering.

Main Results:

  • Induced pluripotent stem cells (iPSCs) and iPSC-derived cardiomyocytes (iPSC-CMs) offer hope for cardiac regeneration.
  • Significant progress has been made in generating pure iPSC-CM populations.
  • Challenges remain concerning cell survival, retention, arrhythmogenicity, and immune response.

Conclusions:

  • Cardiac cell therapy, particularly using iPSC-CMs, is a promising approach for heart regeneration.
  • Overcoming challenges in cell engraftment, safety, and immune response is crucial for clinical translation.
  • Continued research in enhancing cell therapy efficacy and safety is essential for treating heart failure.